TP53 and pancreatic neoplasm: In contrast, SW1990, a pancreatic cancer cell line with mutationally activated KRAS but bearing wild type tumour suppressor P53, displayed a statistically significant dose-dependent reduction of cell number in response to JVG045 treatment (IC50 = 5.4 μM; One-way ANOVA, F (5, 12)=8.208, p = 0.0014; Fig. 5a).